Skip to main content
    A

    Alto Neuroscience, Inc. (ANRO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NYSE

    $27.14
    -2.40 (-8.12%)

    Market Cap: $1.18B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Alto Neuroscience, Inc. (ANRO) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Alto Neuroscience reported EPS of -$0.54, above the -$0.60 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(8/12)
    Avg Surprise
    -33.42%
    Streak
    2 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.65
    Range-$0.78 - -$0.54
    13 analysts
    Revenue Consensus
    N/A
    RangeN/A
    11 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.74
    Range-$1.02 - -$0.57
    4 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.80+8.4%
    60d ago-$0.80+8.6%
    30d ago-$0.80+8.6%
    7d ago-$0.77+4.5%
    Current-$0.74
    Revenue Consensus
    N/A
    RangeN/A
    6 analysts

    Next Report

    ANRO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    Earnings History

    Of the 12 quarters below that had an estimate, ANRO beat 8 and missed 4. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 365.27% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$0.54-$0.60-$0.89 - -$0.60+10.00%BeatN/A70 up, 1 downNov 10, 2026
    Jun 30, 2026-$0.65-$0.71-$0.96 - -$0.57+8.45%BeatN/A60 up, 1 downAug 12, 2026
    Mar 31, 2026-$0.80-$0.50-$0.53 - -$0.48-60.00%MissN/A20 up, 0 downMay 13, 2026
    Dec 31, 2025-$0.45-$0.66N/A+31.82%BeatN/A10 up, 0 downMar 16, 2026
    Sep 30, 2025-$0.52-$0.64-$0.64 - -$0.64+18.75%BeatN/A10 up, 0 downNov 12, 2025
    Jun 30, 2025-$0.65-$0.60N/A-8.33%MissN/AN/A0 up, 0 downAug 13, 2025
    Mar 31, 2025-$0.56-$0.62N/A+9.68%BeatN/AN/A0 up, 0 downMay 14, 2025
    Dec 31, 2024-$0.52-$0.55N/A+5.45%BeatN/AN/A0 up, 0 downMar 20, 2025
    Sep 30, 2024-$0.62-$0.64-$0.76 - -$0.50+3.13%BeatN/A60 up, 0 downNov 12, 2024
    Jun 30, 2024-$0.60-$0.67N/A+10.45%BeatN/AN/AN/AAug 13, 2024
    Mar 31, 2024-$0.76-$0.46N/A-65.22%MissN/AN/AN/AMay 14, 2024
    Dec 31, 2023-$7.77-$1.67N/A-365.27%MissN/AN/AN/AFeb 5, 2024
    Last 12 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Sep 30, 2026-$2.44N/A
    Jun 30, 2026-$1.90N/A
    Sep 30, 2025-$2.25N/A
    Sep 30, 2024-$9.75N/A

    Frequently Asked Questions About ANRO

    Did ANRO beat earnings estimates last quarter?

    Yes. Alto Neuroscience reported EPS of -$0.54 for the quarter ended Sep 30, 2026, above the -$0.60 estimate, a 10.00% surprise.

    What EPS do analysts expect from ANRO next quarter?

    The consensus EPS estimate for Alto Neuroscience for the quarter ending Dec 31, 2026 is -$0.65 from 13 analysts, with estimates from -$0.78 to -$0.54.

    How often does ANRO beat earnings estimates?

    Alto Neuroscience beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +1.98%.